Evidence map›Paper›PMID 28371058›Full record

ArticleThoracic cancer2017

Development of a prognosis-prediction model incorporating genetic polymorphism with pathologic stage in stage I non-small cell lung cancer: A multicenter study.

Won Kee Lee, Shin Yup Lee, Jin Eun Choi, Yangki Seok, Eung Bae Lee, Hyun Cheol Lee, Hyo-Gyoung Kang, Seung Soo Yoo, Myung Hoon Lee, Sukki Cho and 9 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Won Kee LeeBiostatistics Medical Research Collaboration Center, Kyungpook National University Hospital and Kyungpook National University School of Medicine, Daegu, South Korea.
Shin Yup LeeDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.
Jin Eun ChoiDepartment of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, South Korea.
Yangki SeokLung Cancer Center, Kyungpook National University Medical Center, Daegu, South Korea.
Eung Bae LeeLung Cancer Center, Kyungpook National University Medical Center, Daegu, South Korea.
Hyun Cheol LeeDiagnosis and Prediction Biotechnology, School of Medicine, Kyungpook National University, Daegu, South Korea.
Hyo-Gyoung KangDepartment of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, South Korea.
Seung Soo YooDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.
Myung Hoon LeeDiagnosis and Prediction Biotechnology, School of Medicine, Kyungpook National University, Daegu, South Korea.
Sukki ChoDepartment of Thoracic and Cardiovascular Surgery, Seoul National University School of Medicine, Seoul, South Korea.
Sanghoon JheonDepartment of Thoracic and Cardiovascular Surgery, Seoul National University School of Medicine, Seoul, South Korea.
Young Chul KimDepartment of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
In Jae OhDepartment of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
Kook Joo NaDepartment of Thoracic and Cardiovascular Surgery, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
Chi Young JungDepartment of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.
Chang-Kwon ParkDepartment of Thoracic and Cardiovascular Surgery, Keimyung University School of Medicine, Daegu, South Korea.
Mi-Hyun KimDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, South Korea.
Min Ki LeeDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, South Korea.
Jae Yong ParkDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis multicenter study was performed to develop a prognosis-prediction model incorporating genetic polymorphism with pathologic stage for surgically treated non-small cell lung cancer (NSCLC) patients.

methodsA replication study including 720 patients and a panel of eight single nucleotide polymorphisms (SNPs), which predicted the prognosis of surgically treated NSCLC in our previous study, was conducted. Using the combined cohort of current and previous studies including 1534 patients, a nomogram for predicting overall survival was made using Cox proportional hazards regression.

resultsAmong the eight SNPs, C3 rs2287845, GNB2L1 (alias RACK1), and rs3756585 were significantly associated with overall survival. A nomogram was constructed based on pathologic stage and the genotypes of the two SNPs, and the risk score was calculated for each patient in the combined cohort. Using the prognosis-prediction model, we categorized patients into low, intermediate, and high-risk groups, which had greater accuracy in predictive ability (log-rank statistics = 54.66) than the conventional tumor node metastasis staging (log-rank statistics = 39.56). Next, we generated a prognosis-prediction model for stage I to identify a subgroup of potential candidates for adjuvant chemotherapy. Notably, 97 out of 499 stage IB patients were classified as high-risk patients with a similar prognosis to stage II patients, suggesting the benefit of adjuvant chemotherapy.

conclusionsThis prognosis-prediction model incorporating genetic polymorphism with pathologic stage may lead to more precise prognostication in surgically resected NSCLC patients. In particular, this model may be useful in selecting a subgroup of stage IB patients who may benefit from adjuvant chemotherapy.

Indexed as

PrognosisAdultAgedCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantDisease-Free SurvivalGenotypeHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingPolymorphism, Single NucleotideRisk FactorsNSCLCpolymorphismprognosisstagesurgery

Identifiers

PMID28371058
PMCPMC5415483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.